Education and training

Transkript

1 Dr. Barbara Lawrenz graduated from medical school in Berlin and Giessen, Germany, and was a resident in gynecology and obstetrics at the hospital in Reutlingen, Germany, a teaching-hospital of the university Tuebingen, Germany. After her specialization in Gynecology and Obstetrics ( Facharzt ) she worked as a senior physician in different hospitals in gynecology and obstetrics in leading positions before joining the women s university hospital in Tuebingen, Germany. There she obtained additional specializations in Obstetrics and Perinatal Medicine as well as in Gynecological Endocrinology and Reproductive Medicine. From 2007 until 2013 she was head of the IVF-unit of the Women s university hospital in Tuebingen, Germany. During this time, she had a special focus on fertility preservation before cytotoxic therapy in women with malignant diseases and on pregnancy after breast cancer. She was a member of the steering committee of the network FertiPROTEKT, a network which is specialised on the collection of data regarding fertility preservation counseling and treatment and the optimization of fertility preservation treatments. This network comprises university-based and private IVF-centers in Germany, Austria and Switzerland. With her Habilitation thesis: Fertility preservation before cytotoxic therapy in young girls, adolescents and premenopausal women, she obtained the designation lecturer ( Privatdozentin ) and the teaching license of the University of Tuebingen, Germany, for Gynecology and Obstetrics. She authored / was co-author in 35 peer-reviewed articles and additional numerous articles in German journals. Since 2013 she is working as an IVF-specialist in Abu Dhabi, UAE, and she joined IVI Middle East Fertility Clinic in Abu Dhabi in 02 / Her special focus is now on luteolysis and luteal phase support in IVF-treatments. Education and training

2 2012: Habilitation thesis: Fertility preservation before cytotoxic therapy in young girls, adolescents and premenopausal women. Obtaining the designation lecturer ( Privatdozentin ); Teaching license of the university of Tuebingen for Obstetrics and Gynecology : Member of the steering committee of the network FertiPROTEKT 2011: Certificate for University Teaching and Learning in Medicine 2007: Specialization in gynecological endocrinology and reproductive medicine 2004: Specialization in obstetrics and perinatal medicine 1995: Specialist in gynecology and obstetrics 1991: Doctoral dissertation: Determination of Protein C with capillary methods Publications: 1. Lawrenz B, Humaidan P, Kol S, Fatemi HM. GnRHa trigger and luteal coasting A new approach for the OHSS high-risk patient? RBMonline 2017, accepted for publication. 2. Lawrenz B, Samir S, Melado L, Ruiz F, Fatemi HM. Luteal phase serum progesterone levels after GnRH-agonist trigger - how low is still high enough for an ongoing pregnancy? Gynecol Endocrinol Oct 16: Bayram A, Elkhatib I, Arnanz A, Linan A, Ruiz F, Lawrenz B, Fatemi HM. What Drives Embryo Development? Chromosomal Normality or Mitochondria? Case Rep Genet. 2017;2017: Lawrenz B, Garrido N, Samir S, Ruiz F, Melado L, Fatemi HM. Individual luteolysis pattern after GnRH-agonist trigger for final oocyte maturation. PLoS One May 1;12(5):e Lawrenz B, Fatemi HM. Effect of progesterone elevation in follicular phase of IVFcycles on the endometrial receptivity. Reprod Biomed Online Apr;34(4): Lawrenz B, Ruiz F, Engelmann N, Fatemi HM. Individual luteolysis post GnRH-agonisttrigger in GnRH-antagonist protocols. Gynecol Endocrinol Apr;33(4): Lawrenz B, Beligotti F, Engelmann N, Gates D, Fatemi HM. Impact of gonadotropin type on progesterone elevation during ovarian stimulation in GnRH antagonist cycles. Hum Reprod Nov;31(11):

3 8. von Wolff M, Giesecke D, Germeyer A, Lawrenz B, Henes M, Nawroth F, Friebel S, Rohde A, Giesecke P, Denschlag D. Characteristics and attitudes of women in relation to chosen fertility preservation techniques: a prospective, multicenter questionnairebased study with 144 participants. Eur J Obstet Gynecol Reprod Biol Jun;201: Lawrenz B, Mahajan N, Fatemi HM. The effects of cancer therapy on women's fertility: what do we know now? Future Oncol Jul;12(14): Gurbuz AS, Deveer R, Ozcimen N, Ozcimen EE, Lawrenz B, Banker M, Garcia-Velasco JA, Fatemi HM. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases. Gynecol Endocrinol. 2016;32(1): Henes M, Froeschlin J, Taran FA, Brucker S, Rall KK, Xenitidis T, Igney-Oertel A, Lawrenz B, Henes JC. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-müllerian hormone levels. Rheumatology (Oxford) Sep;54(9): Schleussner E, Kamin G, Seliger G, Rogenhofer N, Ebner S, Toth B, Schenk M, Henes M, Bohlmann MK, Fischer T, Brosteanu O, Bauersachs R, Petroff D; ETHIG II group. (Collaborators: Bauersachs R, Beuter-Winkler P, Bohlmann MK, Brosteanu O, Brückmann A, Dudenhausen J, Ebner S, Fischer T, Grüβner S, Henes M, Illing R, Kamin G, Kemkes-Matthes B, Lachmann R, Lawrenz B, Neuhaus P, Nitzsche K, Petroff D, Rogenhofer N, Scheler C, Schenk M, Schleussner E, Seeger S, Seeliger C, Seliger G, Thaler C, Toth B.). Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. Ann Intern Med May 5;162(9): Henes M, Neis F, Krämer B, Walter C, Brucker S, Von Wolff M, Rothmund R, Lawrenz B, Rall K. Possibilities of fertility preservation in young patients with ovarian cancer. Anticancer Res Jul;34(7): Deubzer B, Weber K, Lawrenz B, Schweizer R, Binder G. Anti-mullerian hormone deficiency in girls with congenital multiple pituitary hormone deficiency. J Clin Endocrinol Metab Jun;99(6):E

4 15. Schaible AM, Koeberle A, Northoff H, Lawrenz B, Weinigel C, Barz D, Werz O, Pergola C. High capacity for leukotriene biosynthesis in peripheral blood during pregnancy. Prostaglandins Leukot Essent Fatty Acids Sep;89(4): Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, Henes M; Centers of FertiPROTEKT Network. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-hodgkin-lymphoma--evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril Jul;98(1): Henes JC, Henes M, von Wolff M, Schmalzing M, Kötter I, Lawrenz B. Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network. Clin Exp Rheumatol Jan-Feb;30(1 Suppl 70):S Henes M, Henes JC, Neunhoeffer E, Von Wolff M, Schmalzing M, Kötter I, Lawrenz B. Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network. Lupus Aug;21(9): Lawrenz B, Henes M, Neunhoeffer E, Fehm T, Huebner S, Kanz L, Marini P, Mayer F. Pregnancy after successful cancer treatment: what needs to be considered? Onkologie. 2012;35(3): Beraldi A, Brathuhn S, Heussner P, König V, Lawrenz B. The young cancer patient: psychosocial problems and concepts in rehabilitation. Onkologie. 2011;34 Suppl 5: Lawrenz B, Rothmund R, Neunhoeffer E, Huebner S, Henes M. Fertility preservation in prepubertal girls prior to chemotherapy and radiotherapy--review of the literature. J Pediatr Adolesc Gynecol Oct;25(5): Lawrenz B, Kraemer B, Wallwiener D, Witte M, Fehm T, Becker S. Lower extremity compartment syndrome after laparoscopic radical hysterectomy: brief report of an unusual complication of laparoscopic positioning requirements. J Minim Invasive Gynecol Jul-Aug;18(4): Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, Fehm T, Kïtter I.Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-muellerian hormone. Lupus Oct;20(11):

5 24. Lawrenz B, Henes M, Neunhoeffer E, Fehm T, Lang P, Schwarze CP. Fertility preservation in girls and adolescents before chemotherapy and radiation - review of the literature. Klin Padiatr May;223(3): von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B. Fertility preservation in women--a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet Aug;284(2): Lawrenz B, Henes M, Neunhoeffer E, Kraemer B, Fehm T. Fertility conservation in breast cancer patients. Womens Health (Lond) Mar;7(2): Lawrenz B, Fehm T, Neunhoeffer E, Krämer B, Soekler M, Kanz L, Henes M, Mayer F. Fertility preservation in young female lymphoma patients: review of available options and initial experiences with their implementation in clinical routine. Onkologie. 2011;34(3): Henes M, Henes JC, Schmalzing M, Neunhoeffer E, Rothmund R, Kötter I, Lawrenz B. Fertility preservation for young patients with autoimmune diseases and the need for cytotoxic treatment. Clinical experiences from interdisciplinary consultation. Z Rheumatol Feb;70(2): Lawrenz B, Banys M, Henes M, Neunhoeffer E, Grischke EM, Fehm T. Pregnancy after breast cancer: case report and review of the literature. Arch Gynecol Obstet Apr;283(4): Lawrenz B, Jauckus J, Kupka MS, Strowitzki T, von Wolff M. Fertility preservation in >1,000 patients: patient's characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet Mar;283(3): Huober-Zeeb C, Lawrenz B, Popovici RM, Strowitzki T, Germeyer A, Stute P, von Wolff M. Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. Fertil Steril Jan;95(1): Lawrenz B, Jauckus J, Kupka M, Strowitzki T, von Wolff M. Efficacy and safety of ovarian stimulation before chemotherapy in 205 cases. Fertil Steril Dec;94(7):

6 33. Lawrenz B, Neunhoeffer E, Henes M, Lessmann-Bechle S, Krämer B, Fehm T. Management of fertility preservation in young breast cancer patients in a large breast cancer centre. Arch Gynecol Obstet Nov;282(5): Pergola C, Dodt G, Rossi A, Neunhoeffer E, Lawrenz B, Northoff H, Samuelsson B, Rådmark O, Sautebin L, Werz O. ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci U S A Dec 16;105(50): von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril Oct;92(4): Publications in German Journals: 1. Lawrenz B, Fatemi HM. Sonne, Vitamin D und Fertilität. Gynäkologische Endokrinologie, 2015;3: Lawrenz B, Grischke EM, Fehm T. Schwangerschaft nach Mammakarzinom. Frauenheilkunde up2date 2011; 3. Beraldi A, Brathuhn S, Heußner P, König V, Lawrenz B. Der junge Krebspatient: Psychosoziale Probleme und Konzepte der Rehabilitation. Onkologie 2011;34(suppl 5): Borchmann P, Heußner P, Hilgendorf I, Katalinic A, Lawrenz B, Neubauer A, Willenbacher W, Wörmann B (authors in alphabetical order). Onkopedia 2011: Heranwachsende und junge Erwachsene (AYA, Adolescents and Young Adults) 5. Neunhoeffer E, Lawrenz B. Therapieoptionen der Endometriose. Arzneimitteltherapie 2011;29: Grischke EM, Lawrenz B, Fehm T, Hoopmann M, Abele H, Kagan KO. Mammkarzinom und Schwangerschaft: Diagnostik, Therapie, Einfluss auf Fertilität und weitere Schwangerschaften. Geburtshilfe und Frauenheilkunde 2010;70: Von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B. Fertilitätsprotektion bei Frauen. Geburtshilfe und Frauenheilkunde 2010;70:R85-R100

7 8. Lawrenz B, von Wolff M. FertiPROTEKT-Netzwerk für fertilitätsprotektive Maßnahmen bei Chemo- und Strahlentherapie. Journal für Reproduktionsmedizin und Endokrinologie 2010;7: Lawrenz B, von Wolff M, Neunhoeffer E, Fehm T, Mayer F. Fertilitätserhalt bei Krebs. Tumordiagnostik und Therapie 2010;31: Lawrenz B. Vorgehen bei Adnextorsion. Chirurgische Praxis 2010;72: Lawrenz B, Henes M, Neunhoeffer E, Fehm T, von Wolff M. Fertilitätsprotektion aktuell. Geburtshilfe und Frauenheilkunde 2010;70: Henes M, Lessmann-Bechle S, Becker S, Lawrenz B. Therapie des polyzystischen Ovarsyndroms (PCOS). Arzneimitteltherapie 2009;27: Lawrenz B. Vorgehen bei Adnextorsion. Gynäkologische Praxis2009;33: Lawrenz B, Fehm T, Henes M, von Wolff M. Fertilitätserhalt vor Chemotherapie - was ist heute möglich? Frauenheilkunde up2date 2009;2: Lawrenz B, Lessmann-Bechle S, Neunhoeffer E, Henes M. Kinderwunsch wie lange? Geburtshilfe und Frauenheilkunde 2009;69: Lawrenz B, Thaler C, Frambach T, Zeeb C, Popovici RM, Strowitzki T, von Wolff M. Fertilitäterhaltende Maßnahmen: Der Beginn der ovariellen Stimulation zur Gewinnung von Oozyten ist in der Lutealphase möglich. Geburtshilfe und Frauenheilkunde 2009;69: Lawrenz B, Wallwiener D. Adipositas und Sterilität. Pharma Focus Gynäkologie 2008;3: Lawrenz B, Neunhoeffer E. Diagnostik und Therapie der Sterilität. Frauenheilkunde up2date 2008;2: Lawrenz B, Neunhoeffer E. Syndrom der polyzystischen Ovarien (PCOS), Insulinresistenz und Sterilität bei adipösen Frauen. Geburtshilfe und Frauenheilkunde 2008;68: Lawrenz B, Binder H, Zeeb C, von Wolff M, Fehm T. Chemotherapie und Fertilitätserhalt was ist möglich? Geburtshilfe und Frauenheilkunde 2007;67:490-2.